Measles immunity gap among reproductive-age women participating in a simulated HIV vaccine efficacy trial in Zambia

Figures & data

Figure 1. Simulated vaccine efficacy trial participant flowchart (N = 159).

Table 1. Sociodemographics of Zambian women enrolled in SiVET.

	Group A (N=79)		Group B (N=80)		Total (N=159)
	n	%	n	%	n	%
Antibody status
Measles positive	58	73	60	75	118	75
Mumps positive	74	94	73	91	147	93
Rubella positive	74	94	77	96	151	95
Place of residence
Lusaka	36	46	43	54	79	49
Ndola	43	54	37	46	80	51
Age (years)
18 -20	16	20	15	19	31	19
21-23	20	25	32	40	52	33
24-28	20	25	17	21	37	23
29-39	23	30	16	20	39	25
Number of live births
0	5	6	7	9	12	8
1-2	55	70	54	67	109	69
3-4	15	19	16	20	31	19
5-6	4	5	3	4	7	4
Marital status^a
Never married	56	72	55	69	111	70
Divorced/separated	20	25	24	30	44	28
Widowed	2	3	1	1	3	2
Education level
Primary	38	48	36	45	74	47
Secondary	31	39	41	51	72	45
College	3	4	0	0	3	2
None of the above	7	9	3	4	10	6
High-risk group
Female sex worker	31	39	28	35	59	37
Single mother	48	61	52	65	100	63
Measles pre-vaccination knowledge from VES^b
Yes	77	99	77	97	154	97
No	1	1	2	3	3	2
Mumps pre-vaccination knowledge from VES^b
Yes	74	96	74	94	148	93
No	3	4	5	6	8	5
Rubella pre-vaccination knowledge from VES^c
Yes	15	19	11	14	26	16
No	63	81	67	86	130	82

Table 2. Antibody status results pre- and post-vaccination.

	Pre-Vaccination (N= 159)		Post-Vaccination (N=154)
	n	%	n	%	p-value
Measles^a
Negative	30	19	2	1
Equivocal	9	6	2	1
Positive	118	75	150	98	<.05
Mumps
Negative	9	6	2	1
Equivocal	0	0	0	0
Positive	150	94	152	99	<.05
Rubella
Negative	4	3	0	0
Equivocal	0	0	0	0
Positive	155	97	154	100	.123

Two participants were missing pre-vaccination samples for measles.